article thumbnail

Moderna sues Pfizer/BioNTech over Covid patent

Drug Discovery World

The lawsuits, which were made in the United States and Germany, state that Pfizer and BioNTech’s Covid-19 vaccine Comirnaty infringes Moderna’s patents for its mRNA technology filed between 2010 and 2016. Moderna first started developing this chemical modification in 2010 and validated it in human trials in 2015.

Vaccine 130
article thumbnail

AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development

The Pharma Data

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Peijia Medical and HighLife Enter Into License and Technology Transfer Agreement for Transeptal Mitral Valve Replacement in Greater China

The Pharma Data

” Under the License Agreement, Peijia and HighLife will establish a joint review committee to enhance a mutual sharing of information about the development as well as commercialization of the TMVR products, further deepening cooperation between the two companies. SUZHOU, China and PARIS , Dec. About HighLife.

article thumbnail

Investigating antipsychotics in a Parkinson’s disease psychosis model

Drug Target Review

Clozapine induced a significantly different brain state and pimavanserin, the only licensed compound for PD-P, turned out to be more similar to Mesdopetam on the global scale. In 2010 he was appointed Executive Vice President, Research at NeuroSearch. Nicholas continued to serve as CEO of NeuroSearch Sweden through 2012.

Disease 105
article thumbnail

Long-Term Care Workers Often Hold Multiple Jobs

The Pharma Data

from the University of New Hampshire in Durham, and colleagues used data from the Current Population Survey (2010 to 2019) to document the rate of nursing and long-term care workers who hold second jobs. percent of licensed practical nurses and registered nurses held second jobs. Baughman, Ph.D.,

Nurses 52
article thumbnail

FDA Knows Its Own Strength—and It Includes Concentration

FDA Law Blog: Biosimilars

This of course, make sense—after decades of experience implementing the Hatch-Waxman, Congress and FDA had learned a few new tricks by 2009/2010. Amongst other things, FDA co-opted many of the same definitions for key terms for implementation of the BPCIA. mL), to be biosimilar to or interchangeable with High Concentration Humira (e.g.,

FDA 59
article thumbnail

Collaboration with the LIBD to Develop Centrally Acting COMT Inhibitors

The Pharma Data

In partnering with the Lieber Institute, Boehringer Ingelheim has in-licensed preclinical pipeline candidates, representing a first-in-class approach for targets in neuropsychiatric disorders. The potential of centrally acting COMT inhibitors has not yet been evaluated in the clinic due to the unavailability of such compounds.